Nutriband Inc. (NASDAQ: NTRB) has reached a significant milestone, marking five years since its listing on the Nasdaq Capital Market. In a letter to shareholders, CEO Gareth Sheridan reflected on the company's journey and outlined the path ahead, emphasizing the progress of its lead product candidate, AVERSA(TM) Fentanyl, an abuse-deterrent fentanyl patch.
Since October 1, 2021, Nutriband has advanced AVERSA(TM) Fentanyl from feasibility studies through commercial manufacturing scale-up. The company has also expanded its patent protection and engaged with the U.S. Food and Drug Administration (FDA) on the product's development. These achievements position Nutriband to potentially address the ongoing opioid crisis with a novel transdermal technology.
Looking forward, Sheridan stated that the company's priorities include manufacturing clinical supplies for a Human Abuse Liability study, filing an Investigational New Drug (IND) application, initiating clinical studies, and advancing AVERSA(TM) Fentanyl toward a New Drug Application (NDA) filing. The IND application is a critical step that, if accepted, would allow Nutriband to begin human clinical trials in the United States.
The implications of this announcement are substantial. If successful, AVERSA(TM) Fentanyl could become the first abuse-deterrent fentanyl patch, offering a safer alternative for patients requiring chronic pain management while reducing the risk of abuse, misuse, diversion, and accidental exposure. The product incorporates Nutriband's proprietary AVERSA(TM) technology, which can be applied to any transdermal patch to deter abuse of drugs with abuse potential. This could open up licensing opportunities with other pharmaceutical companies.
For investors, the five-year anniversary and the outlined milestones signal a clear strategic direction. The company is transitioning from research and development toward clinical and regulatory phases, which are essential for eventual commercialization. Success in these endeavors could lead to significant revenue streams and partnerships, but also carries inherent risks associated with drug development. The shareholder letter serves to reassure investors of Nutriband's commitment to bringing its lead product to market.
Nutriband's progress is also noteworthy in the broader context of the pharmaceutical industry, where abuse-deterrent formulations are increasingly sought after by regulators and healthcare providers. The company's focus on transdermal products, specifically its AVERSA(TM) technology, differentiates it from other players. As the opioid epidemic continues to claim lives, innovative solutions like AVERSA(TM) Fentanyl could play a crucial role in harm reduction.
The full press release can be viewed at https://ibn.fm/Bg8PU. For more information about Nutriband, visit their website at www.nutriband.com. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. This press release is distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, offering services such as editorial syndication to 5,000+ outlets and social media distribution.
